99 related articles for article (PubMed ID: 17635152)
1. Targeting aggressive B-cell lymphomas with cell-penetrating peptides.
Melnick A
Biochem Soc Trans; 2007 Aug; 35(Pt 4):802-6. PubMed ID: 17635152
[TBL] [Abstract][Full Text] [Related]
2. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2009 Dec; 27(4):182-5. PubMed ID: 19670467
[TBL] [Abstract][Full Text] [Related]
3. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
[TBL] [Abstract][Full Text] [Related]
4. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
Reiter A; Klapper W
Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
[TBL] [Abstract][Full Text] [Related]
6. Cell-penetrating peptides in drug development: enabling intracellular targets.
Chen L; Harrison SD
Biochem Soc Trans; 2007 Aug; 35(Pt 4):821-5. PubMed ID: 17635156
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
9. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
[TBL] [Abstract][Full Text] [Related]
10. Applications of cell-penetrating peptides in regulation of gene expression.
Järver P; Langel K; El-Andaloussi S; Langel U
Biochem Soc Trans; 2007 Aug; 35(Pt 4):770-4. PubMed ID: 17635145
[TBL] [Abstract][Full Text] [Related]
11. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
[TBL] [Abstract][Full Text] [Related]
12. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Abramson JS
Oncologist; 2006 Apr; 11(4):384-92. PubMed ID: 16614234
[TBL] [Abstract][Full Text] [Related]
13. Primary mediastinal large B-cell lymphoma.
Martelli M; Ferreri AJ; Johnson P
Crit Rev Oncol Hematol; 2008 Dec; 68(3):256-63. PubMed ID: 18774728
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment and new agents in diffuse large B-cell lymphoma.
Leonard JP; Martin P; Barrientos J; Elstrom R
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
16. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia.
Ferreira BI; García JF; Suela J; Mollejo M; Camacho FI; Carro A; Montes S; Piris MA; Cigudosa JC
Haematologica; 2008 May; 93(5):670-9. PubMed ID: 18367492
[TBL] [Abstract][Full Text] [Related]
17. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
19. Tumour-homing peptides: tools for targeting, imaging and destruction.
Enbäck J; Laakkonen P
Biochem Soc Trans; 2007 Aug; 35(Pt 4):780-3. PubMed ID: 17635147
[TBL] [Abstract][Full Text] [Related]
20. Primary mediastinal B-cell lymphoma.
Boleti E; Johnson PW
Hematol Oncol; 2007 Dec; 25(4):157-63. PubMed ID: 17575573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
